(Q52934116)

English

[Dose adjustment in patients treated with infliximab in routine rheumatologic care in Germany. Results from the Biologics Register RABBIT].

scientific article published in September 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16534537

[Dose adjustment in patients treated with infliximab in routine rheumatologic care in Germany. Results from the Biologics Register RABBIT]. (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16534537

author name string

A Zink

1

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16534537

J Listing

2

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16534537

A Strangfeld

3

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16534537

E Gromnica-Ihle

4

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16534537

W Demary

5

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16534537

M Schneider

6

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16534537

language of work or name

0 references

publication date

1 September 2006

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16534537

number of pages

6

1 reference

based on heuristic

inferred from page(s)

Zeitschrift fuer Rheumatologie

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16534537

65

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16534537

5

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16534537

441-446

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16534537

https://scigraph.springernature.com/pub.10.1007/s00393-006-0033-8

0 references

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/16534537

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose intensification with infliximab in patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16534537

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16534537

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions

1 reference

https://pubmed.ncbi.nlm.nih.gov/16534537

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Longitudinal analysis of the use of etanercept versus infliximab determined from medical chart audit

1 reference

https://pubmed.ncbi.nlm.nih.gov/16534537

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect

1 reference

https://pubmed.ncbi.nlm.nih.gov/16534537

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16534537

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab dose and charge escalation patterns in managed care

1 reference

https://pubmed.ncbi.nlm.nih.gov/16534537

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

1 reference

https://pubmed.ncbi.nlm.nih.gov/16534537

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16534537

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00393-006-0033-8

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16534537

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16534537

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52934116&oldid=1775431642"